Printer Friendly

Research and Markets: Irritable Bowel Syndrome - Current Irritable Bowel Syndrome Market is Weak Due to the Availability of Limited Treatment Options.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/e79782/irritable_bowel_sy) has announced the addition of GlobalData's new report "Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016" to their offering.

Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016. The report is an essential source of information and analysis on the global irritable bowel syndrome (IBS) market. The report identifies the key trends shaping and driving the global IBS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global IBS sector.

Irritable Bowel Syndrome Market is Forecast to Show Significant Growth until 2016

GlobalData estimated the global IBS market to be worth $1.6 billion in 2009 and forecasts it to grow at 9.1% annually for the next seven years to reach $3 billion by 2016. This growth is primarily attributable to high levels of unmet need in the market which is expected to be served by strong pipeline candidates. The growth will be further supported by the high prevalence rates of the disease. However, the barriers for the IBS market such as the low treatment seeking rate, difficulty in diagnosis and the availability of generics may restrict the market size.

Global IBS Market Forecast ($bn), 2001-2016

Current Irritable Bowel Syndrome Market Is Weak Due to the Availability of Limited Treatment Options

Publisher analyzed the current competitive landscape for IBS drugs and found that the competition is weak. There are four commonly used approved products and a generic for the treatment of IBS. Amitiza from Sucampo Pharmaceuticals, Inc. and Lotronex from GlaxoSmithKline are the two approved drugs present in the market for the treatment of IBS-C and IBS-D respectively. In addition, peppermint oil is used for the treatment of symptoms of IBS including abdominal pain and abdominal distension and is available under the trade names Colpermine and Mintec. Generics do not hold a significant share in the market. GlobalData's analysis of the entire competitive landscape of the branded products shows weak competition between the available treatments for IBS. The competition is weak due to a lack of competing products for Amitiza and Lotronex in IBS-C and IBS-D respectively. The market is under-penetrated and has a huge potential for molecules with better safety and efficacy profiles.

Scope:

* Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.

* Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

* Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.

* Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.

* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

* Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.

Key Topics Covered:

1 Table of contents

2 Irritable Bowel Syndrome: Market Characterization

3 Irritable Bowel Syndrome Market: Competitive Assessment 4 Irritable Bowel Syndrome Market: Pipeline Assessment

5 Irritable Bowel Syndrome Market: Implications for Future Market Competition

6 Irritable Bowel Syndrome Market: Future Players in the Irritable Bowel Syndrome Market

7 IBS Market: Appendix

Companies Mentioned:

* Ironwood pharmaceuticals and Forest laboratories

* Tioga Pharmaceuticals

* Alimentary Health Ltd & P & G

* Lexicon

* Salix Pharmaceuticals

* Astellas Pharma

For more information visit http://www.researchandmarkets.com/research/e79782/irritable_bowel_sy
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 17, 2010
Words:651
Previous Article:AT&T Mobility, Communications Workers of America Reach Tentative Agreement in Southeast Mobility Contract Negotiations.
Next Article:Bayer HealthCare Marks 2010 World Hemophilia Day with a $350,000 Contribution to the World Federation of Hemophilia.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters